Advertisement

A Stool Multitarget mRNA Assay for the Detection of Colorectal Neoplasms

  • Elizabeth Herring
  • Shigeru Kanaoka
  • Eric Tremblay
  • Jean-François Beaulieu
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1765)

Abstract

Noninvasive screening methods for the detection of colorectal cancers (CRC) at curable stages rely on the identification of specific biomarkers. Our group has shown that mRNA stool assays represent a powerful and robust approach for the prediction of colorectal neoplasms. In this methodological chapter, we describe the procedures to isolate good quality stool RNA and the steps to evaluate the levels of specific host mRNA markers such as ITGA6, MYC, and GADD45B using TaqMan-based quantitative and droplet digital PCR approaches.

Key words

Colorectal cancer Diagnosis mRNA Stool qPCR ddPCR 

Notes

Acknowledgments

The original studies were supported by Canadian Institutes of Health Research grants MOP 97836 and PPP 133373. JFB is the recipient of the Canada Chair in Intestinal Physiopathology and a member of the FRQS-funded Centre de Recherche of the Centre Hospitalier Universitaire de Sherbrooke.

The authors thank Bio-Rad Laboratories Canada and Dr. Katia Nadeau for the prolonged trial period with the ddPCR equipment and Dr. Sean C. Taylor for scientific advice.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30.  https://doi.org/10.3322/caac.21332CrossRefPubMedGoogle Scholar
  2. 2.
    Maratt JK, Saini SD (2015) Colorectal cancer screening in the 21st century: where do we go from here? Am J Manag Care 21(7):e447–e449. doi:86282 [pii]PubMedGoogle Scholar
  3. 3.
    Robertson DJ, Imperiale TF (2015) Stool testing for colorectal cancer screening. Gastroenterology 149(5):1286–1293.  https://doi.org/10.1053/j.gastro.2015.05.045. S0016-5085(15)00772-6 [pii]CrossRefPubMedGoogle Scholar
  4. 4.
    Willyard C (2015) Screening: early alert. Nature 521(7551):S4–S5.  https://doi.org/10.1038/521S4a. 521S4a [pii]CrossRefPubMedGoogle Scholar
  5. 5.
    Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J (2006) Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 93(9):1115–1122.  https://doi.org/10.1002/bjs.5349CrossRefPubMedGoogle Scholar
  6. 6.
    Schroy PC 3rd, Lal S, Glick JT, Robinson PA, Zamor P, Heeren TC (2007) Patient preferences for colorectal cancer screening: how does stool DNA testing fare? Am J Manag Care 13(7):393–400. doi:3337 [pii]PubMedGoogle Scholar
  7. 7.
    Lin JS, Piper MA, Perdue LA, Rutter CM, Webber EM, O'Connor E, Smith N, Whitlock EP (2016) Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 315(23):2576–2594.  https://doi.org/10.1001/jama.2016.3332CrossRefPubMedGoogle Scholar
  8. 8.
    Ransohoff DF, Sox HC (2016) Clinical practice guidelines for colorectal cancer screening: new recommendations and new challenges. JAMA 315(23):2529–2531.  https://doi.org/10.1001/jama.2016.7990CrossRefPubMedGoogle Scholar
  9. 9.
    Force USPST, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, Garcia FA, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL (2016) Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 315(23):2564–2575.  https://doi.org/10.1001/jama.2016.5989CrossRefGoogle Scholar
  10. 10.
    Allison JE, Fraser CG, Halloran SP, Young GP (2014) Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver 8(2):117–130.  https://doi.org/10.5009/gnl.2014.8.2.117CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hundt S, Haug U, Brenner H (2009) Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 150(3):162–169CrossRefPubMedGoogle Scholar
  12. 12.
    Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014) Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 160(3):171.  https://doi.org/10.7326/M13-1484. 1819122 [pii]CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    YJ Y, Majumdar AP, Nechvatal JM, Ram JL, Basson MD, Heilbrun LK, Kato I (2008) Exfoliated cells in stool: a source for reverse transcription-PCR-based analysis of biomarkers of gastrointestinal cancer. Cancer Epidemiol Biomarkers Prev 17(2):455–458.  https://doi.org/10.1158/1055-9965.EPI-07-2515. 17/2/455 [pii]CrossRefGoogle Scholar
  14. 14.
    Reck M, Tomasch J, Deng Z, Jarek M, Husemann P, Wagner-Dobler I, Consortium C (2015) Stool metatranscriptomics: a technical guideline for mRNA stabilisation and isolation. BMC Genomics 16:494.  https://doi.org/10.1186/s12864-015-1694-yCrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Stauber J, Shaikh N, Ordiz MI, Tarr PI, Manary MJ (2016) Droplet digital PCR quantifies host inflammatory transcripts in feces reliably and reproducibly. Cell Immunol 303:43–49.  https://doi.org/10.1016/j.cellimm.2016.03.007CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Beaulieu JF, Herring E, Kanaoka S, Tremblay E (2016) Use of integrin alpha 6 transcripts in a stool mRNA assay for the detection of colorectal cancers at curable stages. Oncotarget 7(12):14,684–14,692.  https://doi.org/10.18632/oncotarget.7407CrossRefGoogle Scholar
  17. 17.
    Hamaya Y, Yoshida K, Takai T, Ikuma M, Hishida A, Kanaoka S (2010) Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer. Br J Cancer 102(5):916–921.  https://doi.org/10.1038/sj.bjc.6605564. [pii]CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Herring E, Kanaoka S, Tremblay E, Beaulieu JF (2017) Droplet digital PCR for quantification of ITGA6 in a stool mRNA assay for the detection of colorectal cancers. World J Gastroenterol 23(16):1–8.  https://doi.org/10.3748/wjg.v23.i16.0000CrossRefGoogle Scholar
  19. 19.
    Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C (2012) Cutoff finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 7(12):e51862.  https://doi.org/10.1371/journal.pone.0051862. PONE-D-12-12960 [pii]CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ng EW, Poon TC, Lam HS, Cheung HM, Ma TP, Chan KY, Wong RP, Leung KT, Lam MM, Li K, Ng PC (2013) Gut-associated biomarkers L-FABP, I-FABP, and TFF3 and LIT score for diagnosis of surgical necrotizing enterocolitis in preterm infants. Ann Surg 258(6):1111–1118.  https://doi.org/10.1097/SLA.0b013e318288ea96CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Elizabeth Herring
    • 1
  • Shigeru Kanaoka
    • 2
  • Eric Tremblay
    • 1
  • Jean-François Beaulieu
    • 1
  1. 1.Laboratory of Intestinal Physiopathology, Department of Anatomy and Cell Biology, Faculty of Medicine and Health SciencesUniversité de SherbrookeSherbrookeCanada
  2. 2.Department of GastroenterologyHamamatsu Medical CenterHamamatsuJapan

Personalised recommendations